S. Karger AG

SHERPA: Unknown

People

  1. Janjigian
    Janjigian
  2. Molena
    Molena
  3. Bajorin
    Bajorin
  4. Busam
    Busam
  5. Chen
    Chen
  6. Feldman
    Feldman
  7. Funt
    Funt
  8. Iyer
    Iyer
  9. Jhaveri
    Jhaveri
  10. Rosenberg
    Rosenberg

Groups

  1. Department of Medicine (12)
  2. Gastrointestinal Oncology Service (12)
  3. Solid Tumor Oncology Division (12)
  4. Surgery (3)
  5. Breast Medicine Service (1)
  6. Department of Pathology and Laboratory Medicine (1)
  7. Dermatology Service (1)
  8. Dermatology (1)
  9. Division of Subspecialty Medicine (1)
  10. GME, Medicine (1)
Search Within
  1. "Yelena Janjigian"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (1)
Groups
  1. Department of Medicine (12)
  2. Gastrointestinal Oncology Service (12)
  3. Solid Tumor Oncology Division (12)
  4. Surgery (3)
  5. Breast Medicine Service (1)
  6. Department of Pathology and Laboratory Medicine (1)

More Groups

People
  1. Yelena Janjigian (12)
  2. Daniela Molena (3)
  3. Anne Capozzi (1)
  4. Anthony Rossi (1)
  5. Brendan Guercio (1)
  6. Darren Feldman (1)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (3)
  4. 2021 (3)
  5. 2019 (1)
  6. 2018 (1)

More Years

Publications
  1. Oncology Research and Treatment (11)
  2. Case Reports in Oncology (1)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Möhler, M.; Janjigian, Y.; Al-Batran, S. E.; Wainberg, Z.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L.; Oh, D. Y.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
    Meeting Abstract

    Möhler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Meeting Abstract

    Moehler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, double-blind, placebo-controlled, phase 3 study
    Meeting Abstract

    Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S. E.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
    Meeting Abstract

    Stein, A.; Lordick, F.; Janjigian, Y. Y.; Oh, D. Y.; Lee, K. W.; Steeghs, N.; Chao, Y.; DI Bartolomeo, M.; Garcia, M. D.; Mohammad, N. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Dosiseskalations- und dosiserweiterungsstudie mit trastuzumab-deruxtecan(T-DXd)-monotherapie und -Kombinationen bei patienten mit fortgeschrittenem/ metastasiertem HER2+-magenkarzinom (GC) / adenokarzinom des gastroösophagealen überganges (GEJA): DESTINY-Gastric03
    Meeting Abstract

    Lordick, F.; Janjigian, Y. Y.; Oh, D. Y.; Rha, S. Y.; Lee, K. W.; Steeghs, N.; Chao, Y.; Di Bartolomeo, M.; Díez García, M.; Haj Mohammad, N.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Matterhorn: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, doubleblind, placebo-controlled, phase 3 study
    Meeting Abstract

    Al-Batran, S. E.; Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649
    Meeting Abstract

    Möhler, M.; Shitara, K.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A. C.; Liu, T.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Treatment of metastatic extramammary Paget disease with combination ipilimumab and nivolumab: A case report
    Journal Article

    Guercio, B. J.; Iyer, G.; Kidwai, W. Z.; Lacouture, M. E.; Ghafoor, S.; Rossi, A. M.; Assis, D. N.; Chen, Y. B.; Busam, K. J.; Janjigian, Y. Y.; more...
    Case Reports in Oncology (2021)

    Fulltext@MSK | Save
  • Association of PD-L1 combined positive score (CPS) and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)
    Meeting Abstract

    Haag, G.; Lei, M.; Siemers, N.; Pandya, D.; Chang, H.; Sanchez, T.; Dorange, C.; Harbison, C.; Szabo, P.; Janjigian, Y.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save